Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19:e200–12.
Google ScholarÂ
Rieger CT, Liss B, Mellinghoff S, Buchheidt D, Cornely OA, Egerer G, et al. Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors—Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Oncol. 2018;29:1354–65.
Google ScholarÂ
Miller PDE, Patel SR, Skinner R, Dignan F, Richter A, Jeffery K, et al. Joint consensus statement on the vaccination of adult and paediatric haematopoietic stem cell transplant recipients: Prepared on behalf of the British society of blood and marrow transplantation and cellular therapy (BSBMTCT), the Children’s cancer and Leukaemia Group (CCLG), and British Infection Association (BIA). J Infect. 2023;86:1–8.
Google ScholarÂ
Reynolds G, Hall VG, Teh BW. Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy. Transpl Infect Dis. 2023;25:e14109.
Google ScholarÂ
Hall VG, Alexander AA, Mavandadnejad F, Kern-Smith M, Dang X, Kang R, et al. Safety and immunogenicity of adjuvanted respiratory syncytial virus vaccine in high-risk transplant recipients: an interventional cohort study. Clin Microbiol Infect. 2026;32:161–8.
Google ScholarÂ
Shafat T, Spallne A, Khawaja F, Jiang Y, Jackson J, Nesher L, et al. Respiratory Syncytial Virus Exceeded SARS-CoV-2 and Influenza in Lower Respiratory Infection and Mortality Rates Among Patients With Hematologic Malignancies During the 2023-2024 Respiratory Virus Season. Transpl Infect Dis. 2025;27:e70113.
Google ScholarÂ
Wee LE, Alcantara LS, Aung MK, Arora S, Sim JXY, Ren DD, et al. Severity of Respiratory Syncytial Virus and Other Respiratory Viruses Versus Seasonal Influenza Among Hospitalized Patients With Cancer. Open Forum Infect Dis. 2025;12:ofaf682.
Google ScholarÂ
Einarsdottir S, Lobaugh S, Luan D, Gomez-Llobell M, Subramanian P, Devlin S, et al. Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies. Blood Cancer J. 2025;15:114.
Google ScholarÂ
Ozog S, Krantz EM, Tindbaek K, Munoz J, Liu WL, Chalal C, et al. Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response. Nat Commun. 2026;17:4924.
Hall VG, Nguyen THO, Smibert OC, Allen LF, Sullivan SG, Fox A, et al. Influenza-Specific T-Cell Responses to Vaccination Are Independent of Underlying Hematological Malignancy: Analysis of a Randomized Influenza Vaccination Trial. J Infect Dis. 2025;232:1319–29.
Google ScholarÂ
Nguyen THO, Rowntree LC, Allen LF, Chua BY, Kedzierski L, Lim C, et al. Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells. Cell Rep Med. 2023;4:101017.
Google ScholarÂ
Teh BW, Joyce T, Slavin MA, Thursky KA, Worth LJ. Impact of a dedicated post-transplant vaccination service at an Australian cancer centre. Bone Marrow Transplant. 2017;52:1681–3.
Google ScholarÂ
